Debiopharm Group
24
14M
16
0.53
10
0.33
5
- Areas of investment
Summary
The company was established in Europe in Switzerland. The main department of described Corporate Investor is located in the Lausanne.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Debiopharm Group, startups are often financed by Gilde Healthcare, Venture Kick, Van Herk Ventures. The meaningful sponsors for the fund in investment in the same round are Johnson & Johnson Development Corporation, NextStage, Korys. In the next rounds fund is usually obtained by Johnson & Johnson Development Corporation, PMV Tina Fund, Wellcome Trust.
Besides them, we counted 2 critical employees of this fund in our database.
This Debiopharm Group works on 5 percentage points less the average amount of lead investments comparing to the other organizations. The fund is constantly included in less than 2 deals per year. Speaking about the real fund results, this Corporate Investor is 27 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2000. The high activity for fund was in 2012.
Among the most popular portfolio startups of the fund, we may highlight Agendia, Immunexpress, Spinomix. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Switzerland. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are MOOC, Health Care. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little.
Investments analytics
Analytics
- Total investments
- 24
- Lead investments
- 10
- Exits
- 5
- Rounds per year
- 0.53
- Follow on index
- 0.33
- Investments by industry
- Biotechnology (13)
- Health Diagnostics (10)
- Genetics (7)
- Diagnostic Equipment (6)
- Drug Discovery (5) Show 27 more
- Investments by region
-
- Switzerland (14)
- United States (6)
- Netherlands (1)
- France (2)
- Canada (1)
- Peak activity year
- 2012
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Avg. valuation at time of investment
- 33M
- Group Appearance index
- 0.54
- Avg. company exit year
- 5
- Strategy success index
- 0.30
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Coorpacademy | 26 Oct 2016 | Corporate Training, EdTech, MOOC | Early Stage Venture | 11M | Switzerland, Vaud, Lausanne |
| Tune Insight | 28 Sep 2023 | Software, Data Integration | Seed | 3M | Switzerland, Vaud, Lausanne |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.